Delivery Order SPE2DB22D3501-SPE2DB25FXB76
- Not listed
- The Defense Logistics Agency awarded a $11,174.80 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Xeomin 200 Unit Vials, with completion scheduled for August 8, 2025. This competitively awarded contract, issued without set-aside designation, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $8,381.10 to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin-based therapeutic product used for medical applications. This non-set-aside, competitively awarded contract is issued under a firm fixed price structure with an ultimate completion date of September 19, 2025. The order will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania facility, where the company maintains its corporate...
- The Defense Logistics Agency awarded a $1,215.76 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 50-unit vials of Xeomin, a botulinum toxin product used for medical and therapeutic purposes. This non-set-aside contract was competitively awarded with an ultimate completion date of August 28, 2025, and represents a delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026....
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Xeomin 50 unit vials valued at $10,941.84. This competitively awarded, non-set-aside contract is structured as a firm fixed price delivery order with a completion date of September 10, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order falls under the...
- The Defense Logistics Agency awarded a delivery order valued at $5,587.40 to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic medical applications. This firm fixed-price delivery order, issued on August 14, 2025, with completion targeted for September 5, 2025, represents a non-competitive set-aside award drawn from a larger contract vehicle. The product will be performed and delivered from AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a $3,352.44 delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the procurement of Xeomin 100 unit vials, with an ultimate completion date of September 10, 2025. This firm fixed price, competitively awarded contract utilizes no set-aside designation and is performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's existing Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $6,984.25 for 100-unit vials of Xeomin on July 28, 2025, with an ultimate completion date of August 18, 2025. This firm fixed-price contract, which carries no set-aside designation, will be performed in Conshohocken, Pennsylvania, where the vendor maintains its corporate headquarters. Xeomin is a botulinum toxin product used for therapeutic and cosmetic applications, and this delivery order represents a...
- The Defense Logistics Agency awarded a delivery order valued at $1,676.22 to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used for medical and therapeutic purposes. The award, issued on August 21, 2025, with an ultimate completion date of September 12, 2025, represents a firm fixed price delivery order with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the place of performance and is a major...
- AmerisourceBergen Drug Corp was awarded a firm fixed-price delivery order by the Defense Logistics Agency's Medical Supply Chain on August 23, 2025, for the supply of Xeomin 100 Unit vials. The contract ceiling value is $11,174.80, with an ultimate completion date of September 12, 2025. The work will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. This is a non-set-aside contract awarded through competitive procurement, consistent with AmerisourceBergen's...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency for 100-unit vials of Xeomin, a botulinum toxin product used for medical purposes, valued at $3,352.44. The contract was competitively awarded without set-aside provisions and carries a firm fixed price structure with an ultimate completion date of August 21, 2025. Performance will occur at the contractor's Corporate Office location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its primary...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FXB76Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $23,467.08 to AmerisourceBergen Drug Corp for the supply of Xeomin 100 Unit Vials, with an ultimate completion date of September 19, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company operates as a major pharmaceutical distributor serving federal medical procurement needs. This delivery order falls within AmerisourceBergen's comprehensive pharmaceutical supply mission supporting military and veteran healthcare systems. Xeomin, a botulinum toxin product used in medical and cosmetic applications, joins the company's extensive portfolio of specialty medications, brand-name and generic drugs, vaccines, and medical supplies delivered under the DLA prime vendor arrangement. The non-set-aside award demonstrates AmerisourceBergen's ability to compete successfully for federal medical commodities and reflects the company's critical role in supporting the Defense Health Agency and broader military healthcare operations through flexible, firm fixed-price delivery mechanisms.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $23.5k | 8/28/25 |